Sodium Thiosulfate Anhydrous

Phase 1Small molecule

Sodium Thiosulfate Anhydrous is one of 3 small molecule programs targeting Testicular Germ Cell Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Testicular Germ Cell TumorActive, not recruiting

Testicular Germ Cell TumorPhase 1

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Testicular Germ Cell Tumor

#DrugCompanyPhaseTrials

Jevtana

Sanofi

Approved

—2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 3

Sodium Thiosulfate Anhydrous

CCity of Hope Medical Center

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 1Recruiting

Testicular Germ Cell Tumor

NCT07218913

Clinical

Trials by Indication[1]

Testicular Germ Cell Tumor1 trial

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

Recruiting·—·Phase 1·NCT07218913·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sodium Thiosulfate Anhydrous. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodium Thiosulfate Anhydrous compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sodium Thiosulfate Anhydrous. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — City of Hope Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCity of Hope Medical Center

Sodium Thiosulfate Anhydrous

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Testicular Germ Cell Tumor1 trial

References

Drug Info

Quick Facts

Related News